Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers (A58997) - R3 - Effective February 18, 2022

This coverage article has been revised and published for notice under contract numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).

Effective Date: February 18, 2022

Summary of Article Changes:
Under Article Text added verbiage, "Diffuse Large B-Cell Lymphoma (DLBCL)" to the Indicated Uses and Limitations box.

Under ICD-10 Codes that Support Medical Necessity Group 2: Codes added: C83.30 C83.31 C83.32 C83.33 C83.34 C83.35 C83.36 C83.37 C83.38 C83.39.

Visit the Noridian Medicare Coverage Articles webpage to view the complete listing of coverage articles and/or access the Active, Future, or Retired articles available in the CMS MCD.

 

Last Updated Mar 30 , 2023